---
notetoolbar: Study
tags:
  - HEMOascpi
---

# OVERVIEW OF HEMOSTASIS

## Hemostasis
?
- A system of checks and balances in which the **blood vascular system**, **platelets**, and **coagulation proteins**, in a series of enzymatic reactions, work together to ensure the fluidity of blood.
- Consists of **primary hemostasis**, **secondary hemostasis** and **fibrinolysis**.

### PRIMARY HEMOSTASIS
#### Blood vessels

- **ANTIthrombotic**<br>- Facilitates **blood flow** and **reduces turbulence**::<mark class="red">INTACT</mark> vessels
- Results to <mark class="red">vasoconstriction</mark><br>- Activation of the **intrinsic pathway due to COLLAGEN EXPOSURE** and **extrinsic pathway due to release of TISSUE THROMBOPLASTIN**::<mark class="red">DAMAGED</mark> vessels



#### Platelets
?
- round to oval cells, approximately **2 to 4um** in diameter
- fine purple granules fill the cytoplasm, must be **separated from each other**
> [!NOTE]
> ANucleated cytoplasmic fragments, originated from the megakaryocyte in the bone marrow

##### Phases of Platelet ACTIVATION

Platelets **adhere to collagen** and undergo change **from discs to spiny spheres**. This is **PRIMARY aggregation** and is <mark class="red">reversible</mark>::<mark class="red">Adhesion</mark>
Platelets **release the contents** of their dense granules and alpha granules. The release of these granules constitutes **secondary aggregation** which is <mark class="red">IRREVERSIBLE</mark>.::<mark class="red">Secretion</mark>
In response to chemical changes, these events lead to **platelet aggregation** in which platelet adhere to other platelets.::<mark class="red">Aggregation</mark>

##### Platelet Cell Surface Receptors

Receptor for vWF; **adherence to collagen**::GP <mark class="red">1b/IX/V complex</mark>
Fibrinogen receptor; **platelet plug stabilization**::GP <mark class="red">IIb/IIIa</mark>
**Collagen receptors**::GP <mark class="red">VI</mark>, GP <mark class="red">Ia/IIa</mark>
**Fibronectin receptor**::GP <mark class="red">Ic/IIa complex</mark>
Adherence of platelets to **negatively charged phospholipids**::GP <mark class="red">Ia/IIa</mark>

### SECONDARY HEMOSTASIS
?
- Involves a series of blood protein reactions through a **cascade-like process** that occurs in a **series of four reactions**:
	1. <mark class="red">Initiation</mark>
	2. Activation of <mark class="red">X</mark>
	3. Formation of <mark class="red">thrombin</mark>
	4. Formation of <mark class="red">insoluble fibrin clot</mark>
> [!NOTE]
> ![[Pasted image 20240430163558.png]]
> - describes IN VITRO 


- initiated by the release of <mark class="red">tissue factor/Factor III</mark><br>- TF:VIIa complex (convert X to Xa)<br>- Extrinsic Tenase Complex (TF:VIIa complex + Ca2+ + PF3)::<mark class="red">EXtrinsic</mark> cascade<br>
- initiated by <mark class="red">negatively charged phospholipids</mark><br>- Intrinsic Tenase Complex (FIXa + FVIIIa + Ca2+ + PF3)::<mark class="red">INtrinsic</mark> cascade<br>
(FXa + FVa + Ca2- + PF3)<br>Prothrombin → thrombin::<mark class="red">Prothrombinase complex</mark> <br>


#### COAGULATION FACTORS
?
![[Hemostasis (ASCPi)#^bq7822]]


- Enzyme precursors **II, VII, IX, X, XI, XII, prekallikrein (<mark class="red">2, 7, 9, 10, 11, 12, PK</mark>)**<br>- When **activated become ==SERINE PROTEASES==** (designated by “<mark class="red">a</mark>”)::<mark class="red">Zymogens: proenzymes</mark>
- Non-enzymatic V, VIII, HMWK, tissue factor (thromboplastin)<br>- **(<mark class="red">non-enzymatic 5, 8, HMWK, 3</mark>)**::<mark class="red">Co-factors</mark>
- **<mark class="red">prekallikrein</mark>, <mark class="red">kallikrein</mark>, <mark class="red">HMWK</mark>**<br>- Roles include **coagulation activation** and **fibrinolytic activation**::<mark class="red">Kinin factors</mark>
- I, V, VIII, XIII **(<mark class="red">1, 5, 8, 13</mark>)**<br>- **Most labile**, consumed in **coagulation**, found on **platelets**::<mark class="red">Fibrinogen</mark> group
- II, VII, IX, X **(<mark class="red">2, 7, 9, 10</mark>)**<br>- **Vitamin K <mark class="red">DEPENDENT</mark>**, may be **affected by ==WARFARIN==, ==diet==, ==antibiotics==**::<mark class="red">Prothrombin</mark> group
- XI,XII,HMWK, Prekallikrein **(<mark class="red">11, 12, HMWK, PK</mark>)**<br>- Initiate **intrinsic pathway** and **fibrinolysis**::<mark class="red">Contact</mark> group

#### CELL-BASED MODEL of Coagulation
?
> [!NOTE]
> proposed to replace the traditional cascade
> it more accurately explains coagulation <mark class="red">IN VIVO</mark>
> occurs in 3 OVERLAPPING stages

**Vascular endothelium** and **circulating blood cells** are DISRUPTED; interaction of <mark class="red">FVII</mark> with <mark class="red">TF</mark><br>::<mark class="red">Initiation</mark>
**Platelets**, FV, FVIII and FXI **(<mark class="red">5, 8, 11</mark>)** are **activated by ==THROMBIN==** on the platelet's surface<br>::<mark class="red">Amplification</mark>
Results in **production of an adequate amount of thrombin activity**, **production of temporary plug** at the site of injury and **stops the interruption of blood supply**<br>::<mark class="red">Propagation</mark>


### FIBRINOLYSIS
?
> [!NOTE]
> regulatory mechanism of coagulation cascade
> ![[Pasted image 20240430164906.png]]

Becomes **bound to fibrin** at the time of fibrin polymerization::**<mark class="red">Plasminogen</mark>**
- Serine protease that systematically **digests fibrin**<br>- Also **digests FV, FVIII and fibrinogen (5, 8, 1)**<br><br>- MAIN ENZYME of the fibrinolytic system::**<mark class="red">Plasmin</mark>**


# DISORDERS OF HEMOSTASIS

## QUANtitative Disorders of Primary Hemostasis
?
![[Hemostasis (ASCPi)#^mvgojk]]

<b class="table-column"></b>
[!NOTE] ITP (Immune Thrombocytopenic Purpura)
?
- one of the most common disorders causing SEVERED ISOLATED thrombocytoPENIA
- destruction of platelets (immune-mediated)
- impaired platelet production (immune)
- <mark class="red">IgG</mark> directed to GP <mark class="red">IIb/IIIa</mark>, GP <mark class="red">Ib/IX</mark>, GP <mark class="red">V</mark>

### Distinguishing Features Between TTP and HUS
?
![[Hemostasis (ASCPi)#^ix8hvr]]

[!NOTE] TTP (Thrombotic Thrombocytopenic Purpura)
?
- deficiency of ADAMTS-13 (necessary to form a cleaving protease responsible for digesting large vWF multimers)
- presence of <mark class="red">large vWF multimers</mark>
- Congenital form: <mark class="red">Upshaw-schulman Syndrome</mark> ^3h8lj2

[!NOTE] HUS (Hemolytic Uremic Syndrome)
?
- deficiency in proteins that regulate the alternative pathway
- common in CHILDREN (95%)
- ADULT onset: caused by bacterial infections (<mark class="red">EHEC O157:H7</mark>), <mark class="red">connect tissue</mark> disease, some times of <mark class="red">cancer</mark> ^nmqdtm




## QUALitative Disorders of Platelets
?
![[Hemostasis (ASCPi)#^0fb2m5]]
https://youtu.be/-hpU1-TMlEI?t=3258

↓ vWF or defect in vWF::<mark class="red">Von Willebrand disease</mark>
defect in GP Ib/IX/V complex::<mark class="red">Bernard-Soulier syndrome</mark>
↑ IgA & IgM (coating platelets)::<mark class="red">Paraproteinemia</mark>
↓ plasma fibrinogen::<mark class="red">Afibrinogenemia</mark>
defect in GP IIb/IIIa::<mark class="red">Glanzmann thrombasthenia</mark>
::<mark class="red">Dysfibrinogenemia</mark>
Abnormal platelet aggregation::<mark class="red">Storage pool disorders</mark>
Gray platelet syndrome (abnormalities of platelet granules)::<mark class="red">Alpha-granule deficiency</mark>
Chediak-Higashi<br>Hermansky Pudlak::<mark class="red">Dense-granule deficiency</mark>
inhibit the CYCLOOXYGENASE (needed to convert arachidonic acid → TXA2)::<mark class="red">Aspirin</mark>, <mark class="red">NSAIDs</mark>



### Types of von Willebrand Disease
?
> [!NOTE]
> most common of the CONGENITAL BLEEDING disorders

[!NOTE] ALGORITHM
?
> ```mermaid
> graph TD
> 
> B -.-> D(Abnormal)
> D -.-> E(RIPA aggregation)
> D -.-> F(Collagen binding)
> E -.-> G(Multimer analysis)
> F -.-> G
> 
> subgraph A[Family History]
> H(bleeding from trauma)
> I(excessive bruising)
> J(menorrhagia)
> end
> 
> subgraph B[Laboratory evaluation]
> K(F8 activity)
> L(vWF antigen)
> M(vWF:Ristocetin cofactor)
> end
> 
> subgraph C[Normal]
> N(test for other bleeding disorders)
> O(repeat initial testing in a few weeks)
> end
> 
> A -.-> B
> B -.-> C
> 
> ```

![[Hemostasis (ASCPi)#^mmxl09]]
?
> [!NOTE]
> 1 & 3 (quaL)
> 2 (quaN)

[!NOTE]
?
<mark class="red">vWF</mark> (produced by platelets & endothelial cells; stored in <mark class="red">Weibel-Palade bodies</mark>)

## PLATELET AGGREGATION STUDIES
?
> [!NOTE] Title
> ![[Pasted image 20240430170853.png]]
> (initial wave) due to platelet shape change
> (primary aggregation) reversible
> (secondary aggregation) due to release of internal ADP -  component of dense granules; IRREVERSIBLE

[!NOTE]
?
- Sample (PRP); must be tested w/in 4 hours
- NO aspirin intake 7-10 days BEFORE the test
> [!NOTE] https://youtu.be/-hpU1-TMlEI?t=4707
> ![[Pasted image 20240513082257.png]]

### Interpretation of Platelet Aggregometry Results
?
> [!NOTE]
> take note of X and Y axis

![[Pasted image 20240430170942.png]]::N = ECA; **Abn = Ristocetin**<br><br><mark class="red">von Willebrand dss</mark><br><mark class="red">Bernard-Soulier syndrome</mark><br>-  Giant platelet syndrome<br>-  ↑ GP Ib/IX/V complex
![[Pasted image 20240430170952.png]]::**Abn = ECA**; N = Ristocetin<br><br><mark class="red">Afibrinogenemia</mark><br><mark class="red">Glanzmann's thrombasthenia</mark><br>-  ↓ GP IIb/IIIa<br>-  decrease expression of CD41 & CD61
![[Pasted image 20240430171002.png]]::**Partial = ADP & epi**<br>**Abn = Collagen**<br>N = Ristocetin<br><br>Storage Pool Disorders<br>-  <mark class="red">Chediak- Higashi</mark><br>-  <mark class="red">Hermansky- Pudlak</mark><br>-  <mark class="red">Wiskott-Aldrich</mark><br><br>Defective TXA2 synthesis

[!NOTE]
?
- <mark class="red">Chediak-Higashi</mark>
	-  albinism, recurrent infections, lysosomal granules (+)
	- defect in dense granules
- <mark class="red">Hermanski-Pudlak</mark>
	- triad
	- tyrosinase-positive oculocutaneous albinism
	- accumulation of ceroid-like pigment in macrophages
	- bleeding tendency
- <mark class="red">Wiskott-Aldrich</mark> (prob in BOTH alpha & dense granules)
	- triad
	- thrombocytopenia
	- recurrent infections
	- eczema

[!NOTE]
?
Dense granules (Ca2+, ADP, Pyrophosphates, ATP, serotonin)

## Disorders of Secondary Hemostasis
?
![[Hemostasis (ASCPi)#^jtwrv7]]


## EVALUATION OF SECONDARY BLEEDING DISORDERS

```leaflet
id: mixing-studies
image: [[Pasted image 20240430171519.png]]
defaultZoom: 9
width: 80%
```



[!NOTE]
?
- PT (Extrinsic)
- APTT (INtrinsic)
- ↑PT, N APTT (Extrinsic)
- N PT, ↑ APTT (INtrinsic)
- ↑PT, ↑ APTT (Common)

[!NOTE]
?
at least 50% coag factors = NORMAL
![[Hemostasis (ASCPi)#^eo8t55]]



## Factor VIII inhibitor
?
<mark class="red">Factor VIII (8) inhibitor</mark> is found in **==10%–20% of hemophilia patients== receiving REPLACEMENT THERAPY**. It may also develop in patients with **immunologic problems**, **women after childbirth**, and patients with **lymphoproliferative and plasma cell disorders**, or it may develop **in response to medications**. Factor VIII inhibitor is **an ==IgG immunoglobulin== with an inhibitory effect that is TIME and TEMPERATURE DEPENDENT**. The presence of factor VIII inhibitor causes an **elevated APTT** in the face of a **normal prothrombin time**. The APTT would **NOT BE CORRECTED by mixing studies** if **<mark class="red">LUPUS ANTICOAGULANT</mark> was present**. In addition, lupus anticoagulant is **NOT ASSOCIATED with bleeding** unless it coexists with thrombocytopenia.

[!NOTE]
?
F8 inhibitor
APTT↑, immediate mixing (corrected); incubated mixing ↑

[!NOTE] Lupus anticoagulant
?
Lupus Anticoagulant associated with THROMBOSIS (in VIVO)
Lupus anticoagulant (in VITRO)
APTT↑, immediate mixing (not corrected)

## Thrombophilia
?
> [!NOTE]
> abnormal tendency toward EXCESSIVE thrombosis
![[Hemostasis (ASCPi)#^h7tqpm]]
## INHIBITORS OF COAGULATION

Degrades factor **Va** and **VIIIa** (5a, 8a); targets Vitamin K DEPENDENT factors (↓ protein C values in cases of warfarin OVERDOSE )::<mark class="red">Protein C</mark>
Degrades factor **Va** and **VIIIa** (5a, 8a)<br>Cofactor of Protein C::<mark class="red">Protein S</mark>
**Major inhibitor of thrombin**, also inhibits factors IXa, Xa, Xia. XIIa, kallikrein and plasmin **(9a, 10a, 11a, 12a, kallikrein, plasmin)**::<mark class="red">Anti-thrombin III</mark>
**Inhibits thrombin**::<mark class="red">Heparin cofactor II</mark>
Forms a **complex with ==thrombin==, ==kallikrein== and ==plasmin==**::<mark class="red">α2-macroglobulin</mark>
**Inhibits the ==VIIa-tissue factor complex==**::**EPI (<mark class="red">extrinsic pathway inhibitor</mark>)**<br>**LACI (<mark class="red">lipoprotein associated coagulation inhibitor</mark>)**
**Inactivator of factor XIIa (==12a==) and ==kallikrein==**, it also **inhibits factor Xia (==11a==) and ==plasmin==**::<mark class="red">C1 inhibitor</mark>
**Inhibitor of ==thrombin==, Xa (==10a==) and XIa (==11a==)**::<mark class="red">α1 antitrypsin</mark>

# LABORATORY EVALUATION OF HEMOSTASIS

## TESTS FOR DIFFERENTIAL DIAGNOSIS OF ABNORMAL COAGULATION
?
![[Hemostasis (ASCPi)#^yxvqrj]]

Useful screening procedure for the **EXTRINSIC coagulation** (F7)<br><br>target of **WARFARIN therapy monitoring**<br>Procedure: <mark class="red">PPP</mark> (15k rpm, 15 minutes) + Pt reagent (<mark class="red">Thromboplastin</mark> + <mark class="red">CaCl2</mark>)<br><br>NV: <mark class="red">10 - 12 seconds</mark><br><br>INR::<mark class="red">Prothrombin time</mark>
Most useful procedure for routine screening of coagulation disorders in the **INTRINSIC pathway**. For detecting the **presence of ==circulating anticoagulants (inhibitors)==**, and **monitoring ==HEPARIN therapy==**<br><br>Phospholipid (aka Partial Thromboplastin) + Activator + CaCl<br><br>Activators (Kaolin, Celite, Ellagic acid, Micronized silica)<br><br>NV: <mark class="red">20 - 45 seconds</mark><br>Timing STARTS upon addition of CaCl2::<mark class="red">Activated Partial Thromboplastin Time</mark>
Used to detect deficiencies in prothrombin, fibrinogen and factor V and X **(1, 2, 5, 10)**<br><br>differentiate F7 vs F10 def (prolong)<br><br><mark class="red">Russels viper venom</mark> (powerful coagulant)<br><br>NV: <mark class="red">6 - 10 secs</mark>::<mark class="red">Stypven Time</mark>
Measures the availability of **functional fibrinogen.**<br><br>NV: <mark class="red">10 - 14 secs</mark><br><br>affected by HEPARIN contamination::<mark class="red">Thrombin Time</mark>
Helpful in testing for **functional fibrinogen** when the **thrombin time is PROLONGED because of heparin.**<br><br>uses <mark class="red">Bothrops atrox snake venom</mark> -  Thrombin-LIKE activity<br><br>NOT affected by HEPARIN contamination::<mark class="red">Reptilase time</mark>
Factor XIII deficiency **(13) screening test**<br><br>NO PROLONGATION IN PT, APTT<br><br>aka <mark class="red">Duckert's test</mark><br><br>NV: <mark class="red">insoluble clot</mark><br><br>**slow wound healing**::<mark class="red">5M urea solubility test</mark>
Often helpful for the **detection of <mark class="red">LUPUS ANTICOAGULANT</mark>**<br><br>In VIVO - thrombotic agent; neutralize = HEPARIN<br>In VITRO - anticoagulant; neutralize = PLATELETS<br>::<mark class="red">DRVVT</mark>




## THOMBOELASTROGRAPHY
?
> [!NOTE]
> - holistic unlike coagulation asays
> - measures the interaction of platelets with the coagulation cascade
> - aggregation, clot strengthening, fibrin cross-linking & fibrinolysis
> - represents the **cell based model of hemostasis (initiation, amplification & propagation phase)**
![[Pasted image 20240430174033.png]]


= latency until clot formation begins as defined by an amplitude of 2mm<br>NV: <mark class="red">3 - 9 minutes</mark>::R = <mark class="red">reaction time</mark>
= time from the end of R until the clot reaches 20mm<br>- reflects speed of initial clot formation<br>NV: <mark class="red">0.5 - 3 minutes</mark>::K = <mark class="red">K value</mark>
= angle tangent to the curve of K<br>NV = <mark class="red">54 - 80 degrees</mark>::a = <mark class="red">a angle</mark>
= reflects total clot strength<br>NV: <mark class="red">51 - 78mm</mark>::MA = <mark class="red">maximum amplitude</mark>
= % lysis after 30 minutes<br>- reflects the fibrinolysis stage of clot development::LY30 = <mark class="red">lysis time</mark>



### Interpretation of Thromboelastography Patterns

![[Pasted image 20240430174130.png|200]]::Normal
![[Pasted image 20240430174149.png]]::R = prolonged<br>K = prolonged<br>a = decreased<br>MA = decreased
![[Pasted image 20240430174159.png]]::R = normal<br>K = prolonged<br>a = normal<br>MA = decreased
![[Pasted image 20240430174210.png]]::R = normal<br>MA = decreased<br>LY30 = markdly increased
![[Pasted image 20240430174228.png]]::R = decreased<br>K = shortened<br>a = increased<br>MA = increased
![[Pasted image 20240430174239.png]]::R = decreased<br>K = shortened<br>a = increased<br>MA = increased<br>LY30 = increased
![[Pasted image 20240430174321.png]]::R= prolonged<br>K = prolonged<br>a = decreased<br>MA = decreased

![[Pasted image 20240430174130.png]]::Normal
![[Pasted image 20240430174149.png]]::delayed clot formation<br><br>presence of <mark class="red">Anticoagulants/Factor deficiency</mark>
![[Pasted image 20240430174159.png]]::decreased clot strength<br><br><mark class="red">Platelet blockers</mark>
![[Pasted image 20240430174210.png]]::accelerated clot breakdown<br><br><mark class="red">increased Fibrinolysis</mark>
![[Pasted image 20240430174228.png]]::accelerated clot formation<br><br><mark class="red">HYPERcoagulable state</mark>
![[Pasted image 20240430174239.png]]::accelerated clot formation & breakdown<br><br><mark class="red">Early DIC</mark>
![[Pasted image 20240430174321.png]]::<mark class="red">Late DIC</mark>
